All In Biotech

NDA 204655 · Astrazeneca Lp

Nexium 24hr

Esomeprazole Magnesium · Oral

Last checked: Nov 20, 2026Latest source record: Sep 6, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 28, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

522

102 Phase 3, 23 recruiting

FAERS reports

42,419

34,323 serious, 3,791 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 14, 2024.

Uses treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 28, 2014 Original approval · Type 8 - Partial Rx to OTC Switch LabelLetterReview
1 products under this application
  • NEXIUM 24HR · ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE · CAPSULE, DELAYED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Esomeprazole" as an intervention, any sponsor and status, largest first.

All 522 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease19,478
  • acute kidney injury9,970
  • renal failure7,889
  • renal injury6,117
  • end stage renal disease6,040
  • drug ineffective2,791
  • tubulointerstitial nephritis2,445
  • gastrooesophageal reflux disease2,283
  • nausea1,827
  • pain1,751
  • death1,717
  • off label use1,550

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200446
200572
2006203
2007442
2008772
2009488
2010391
2011385
2012303
2013129
2014741
20151,282
20161,506
20171,362
201811,330
201910,667
20202,444
20212,692
20221,687
20231,408
20241,453
20251,578
20261,038

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 777 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.